Cargando…

P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB

Detalles Bibliográficos
Autores principales:	Harrison, Claire, Mesa, Ruben, Talpaz, Moshe, Gupta, Vikas, Gerds, Aaron T., Klencke, Barbara, Ellis, Catherine, Kawashima, Jun, Donahue, Rafe, Strouse, Bryan, Oh, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431508/ http://dx.doi.org/10.1097/01.HS9.0000971072.43107.6c

Ejemplares similares

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
por: Mesa, Ruben, et al.
Publicado: (2022)

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
por: Mesa, Ruben A., et al.
Publicado: (2023)

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2023)

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
por: Verstovsek, Srdan, et al.
Publicado: (2023)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
por: Palandri, Francesca, et al.
Publicado: (2023)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
por: Masarova, Lucia, et al.
Publicado: (2023)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
por: Masarova, Lucia, et al.
Publicado: (2023)

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
por: Pardanani, A, et al.
Publicado: (2015)

Momelotinib therapy for myelofibrosis: a 7-year follow-up
por: Tefferi, Ayalew, et al.
Publicado: (2018)

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]
por: Vannucchi, A., et al.
Publicado: (2022)

P1044: REAL-WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA
por: Mei, J., et al.
Publicado: (2022)

PB2184: IMPACT OF TRANSFUSION BURDEN ON HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS: POST HOC ANALYSIS OF SIMPLIFY-1 AND -2
por: Mesa, Ruben, et al.
Publicado: (2023)

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
por: Tefferi, A, et al.
Publicado: (2017)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
por: Bassiony, Sarah, et al.
Publicado: (2020)

Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
por: Tefferi, A, et al.
Publicado: (2017)

Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
por: Lisette, Del Corso, et al.
Publicado: (2013)

Hemorheological profiles and chronic inflammation markers in transfusion-dependent and non-transfusion- dependent thalassemia
por: Caprari, Patrizia, et al.
Publicado: (2023)

Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy
por: Barki-Harrington, Liza, et al.
Publicado: (2021)

Red cell alloimmunization and autoantibodies in Egyptian transfusion-dependent thalassaemia patients
por: Ahmed, Azza Mohamed, et al.
Publicado: (2010)

When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia
por: Taher, A T, et al.
Publicado: (2015)

Pre- and Post-transfusion Complement Activation in Transfusion-dependent β-thalassaemia
por: Gavriilaki, Eleni, et al.
Publicado: (2018)

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications
por: Gerds, Aaron T., et al.
Publicado: (2022)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
por: Harrison, Claire N., et al.
Publicado: (2016)

Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies
por: Germing, Ulrich, et al.
Publicado: (2019)

Thymoma masquerading as transfusion dependent anemia
por: Muzamil, Javvid, et al.
Publicado: (2016)

Endocrinopathies complicating transfusion-dependent hemoglobinopathy
por: Al-Agha, Abdulmoein E., et al.
Publicado: (2020)

Pulmonary Functions in Transfusion-Dependent Thalassemia
por: Chandra, Jagdish, et al.
Publicado: (2022)

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)
por: Di Tucci, Anna Angela, et al.
Publicado: (2007)

Red Blood Cell Transfusion
por: West, F. Bernadette, et al.
Publicado: (2015)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
por: Talpaz, Moshe, et al.
Publicado: (2020)

Prevalence and specificities of red cell alloantibodies in transfusion-dependent beta thalassemia patients in Yazd
por: Vaziri, M, et al.
Publicado: (2015)

Amustaline‐glutathione pathogen‐reduced red blood cell concentrates for transfusion‐dependent thalassaemia
por: Aydinok, Yesim, et al.
Publicado: (2019)

5588005 IMPACT OF COVID-19 PANDEMIC TO PRE-TRANSFUSION HEMOGLOBIN LEVEL AND FREQUENCY OF TRANSFUSION IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS IN INDONESIA
por: Dewi, M.K.D., et al.
Publicado: (2023)

Alloimmunization among transfusion-dependent thalassemia patients
por: Sadeghian, Mohammad Hadi, et al.
Publicado: (2009)

Status of Superoxide Dismutase in Transfusion Dependent Thalassaemia
por: Rujito, Lantip, et al.
Publicado: (2015)

Glomerular and Tubular Functions in Transfusion-Dependent Thalassemia
por: Sookaromdee, Pathum, et al.
Publicado: (2018)

Quality of life in transfusion-dependent thalassemia patients
por: Alzahrani, Rizqallah A., et al.
Publicado: (2017)

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
por: Jehangir, Waqas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u5rb1lenbsfoaljqogq5c5lls2